877-RX-CELEBS info@rxcelebs.com REQUEST MORE INFO
Home > NewsIndustry News > Healthcare Updates
  Fierce Pharma
Pfizer rejigs executive roster to put Albert Bourla at Read's right hand
Mon, 13 Nov 2017 16:40:14 +0000
Pfizer now has a chief operating officer and, potentially, a successor to CEO Ian Read. It's Albert Bourla, who's headed up the company's Innovative Health unit since early 2016.
Forget BMS. Pfizer should chase a Biogen buy, analyst suggests
Mon, 13 Nov 2017 16:13:55 +0000
One analyst isn’t sure Pfizer can afford to be behind in both immuno-oncology and Alzheimer’s. And while his peers have suggested bulking up in I-O to solve that issue, he has a different idea.
Ex-Eli Lilly executive Azar wins Trump's nomination for top HHS post
Mon, 13 Nov 2017 16:07:54 +0000
Just days after news that President Donald Trump was set to select ex-Eli Lilly executive Alex Azar for the U.S. government's top healthcare post, the president tweeted his nomination Monday morning.
After much hype, Pfizer finally pulls away from Chinese JV
Mon, 13 Nov 2017 15:43:08 +0000
Talk about Pfizer abandoning its shares in a Chinese joint venture with Zhejiang Hisun Pharma has been circling around for at least a year, and now the talk has become reality. Pfizer has officially sold all of its 49% stake to an investment firm, Sapphire I Holdings.
FDA eyes even more pricing competition with another round of generics moves
Mon, 13 Nov 2017 14:41:14 +0000
Congress hasn't made any progress on drug pricing legislation, but that hasn't stopped the government from acting. Now, FDA Commissioner Scott Gottlieb has unveiled yet another move to step up competition in the generics business.
Takeda, Lundbeck plan U.S. test for depression app in latest beyond-the-pill foray
Mon, 13 Nov 2017 03:56:58 +0000
Takeda is tackling another tech project in beyond-the-pill solutions for major depressive disorder. Along with Lundbeck and Advocate Health Care, it has announced a new study for an app using a “conversational text interface” to track and measure patients’ experience on antidepressant therapies. During the study, users will record medications, moods, side effects and other general well-being measurements every day for 12 weeks.
Novo Nordisk cutting 185 jobs, adding another 70 in commercial revamp
Fri, 10 Nov 2017 16:14:34 +0000
Still dealing with intense pricing pressure in its key diabetes business, Novo Nordisk is embarking on its latest wave of job cuts.
Merck KGaA's Mavenclad, Roche's Perjeta win 'innovative' coverage deals with NHS
Fri, 10 Nov 2017 14:49:57 +0000
Cost watchdogs in England and pharma don't always see eye to eye, but the sides are celebrating two new deals on Merck KGaA's Mavenclad and Roche's Perjeta.
Can AstraZeneca afford its fervent commitment to paying a high dividend?
Fri, 10 Nov 2017 14:47:14 +0000
AstraZeneca CEO Pascal Soriot committed to paying a generous dividend "today, tomorrow, and thereafter," during yesterday's earnings call. But investors can be tough on pharma companies when they fail to live up to such vows, and AZ will face some challenges coming up with the cash to fund its dividend promise.
FiercePharmaAsia—Teva’s China JV? Lupin plants’ roadblock, EOC’s $32M series B
Fri, 10 Nov 2017 14:07:39 +0000
Teva is reportedly looking to form a Chinese joint venture, two of Lupin's plants were hit with a combined FDA warning letter, China's EOC Pharma has raised $32 million to help bring several cancer drugs to market and more.
Heron takes on Merck's Emend with FDA win for antinausea drug Cinvanti
Fri, 10 Nov 2017 05:36:00 +0000
Merck’s drug for chemo-induced nausea and vomiting has some new competition. On Thursday, the FDA approved Cinvanti from California’s Heron Therapeutics, and it’ll go up against the New Jersey pharma giant’s Emend.
Hikma FDA dispute lines Novartis' Sandoz up for Advair coup
Fri, 10 Nov 2017 04:34:14 +0000
Those waiting for Hikma and Vectura’s copy of GlaxoSmithKline blockbuster Advair may be waiting awhile. After receiving a May rejection of the knockoff from the FDA, Hikma now says the partners are locked in a dispute with the agency that won’t be resolved until next year’s first quarter.
Persistence pays off for Dynavax as twice-rejected hepatitis B vaccine wins FDA nod
Thu, 09 Nov 2017 20:52:41 +0000
Dynavax completed the long road to approval for its hepatitis B vaccine Heplisav-B on Thursday, securing an FDA nod after two previous rejections. Now, the company is set to challenge GlaxoSmithKline's Engerix-B and transition into a commercial biotech.
Novartis breast cancer med Kisqali, struggling against Ibrance, finds niche in younger women
Thu, 09 Nov 2017 16:43:46 +0000
Novartis breast cancer med Kisqali has struggled to gain traction in a field dominated by Pfizer blockbuster Ibrance. So it’s going where Ibrance hasn’t.
Eli Lilly counts up 2,300 early retirements in $500M cost-cutting drive
Thu, 09 Nov 2017 15:47:09 +0000
Eli Lilly has persuaded 2,300 employees to take early retirement as part of a companywide streamlining designed to save $500 million. With those settled, the company says it's "on track to achieve" the 3,500 job cuts it outlined in September, with some facilities closing entirely.
AstraZeneca executives try to shift I-O focus with China, Brilinta wins
Thu, 09 Nov 2017 15:39:31 +0000
You know executives are over the immuno-oncology questions when one of them offers to hand out a bottle of champagne to the first person to ask a question about cardiovascular, metabolic or respiratory medicines. And that’s what happened 58 minutes into AstraZeneca’s third-quarter earnings call.
Seqirus investing $52M, adding 100 jobs to U.K. flu vaccine site prompted by thoughts of pandemics
Thu, 09 Nov 2017 14:26:01 +0000
Seqirus will invest another £40 million into its site in the U.K. and add more than 100 jobs so it can shorten the time it takes to manufacture and fill its Fluad vaccine.
Trump poised to nominate ex-Lilly executive Alex Azar for top HHS job: report
Thu, 09 Nov 2017 14:25:38 +0000
Despite blasting pharma for "getting away with murder" on multiple occasions, President Donald Trump is expected to pick a former Eli Lilly executive, Alex Azar, to lead the Department of Health and Human Services.
In whirlwind of court fights and controversy, Outcome Health tries for business as usual
Wed, 08 Nov 2017 18:58:42 +0000
Outcome Health may be fending off lawsuits, allegations, investigations and the media spotlight, but the company still aims to get some work done. As lawyers wrangle and an internal investigation continues, employees are scrambling to secure the company's reputation and keep growing its in-office marketing network and platform.
NICE shoots down Bayer's Stivarga in liver cancer, citing price, clinical questions
Wed, 08 Nov 2017 16:47:49 +0000
Bayer is working to position Stivarga as part of a treatment regimen for those in whom its first-line liver cancer fighter, Nexavar, has failed. But that’s not going to work in England. At least, not yet.
After hep C hit, Merck's antiviral business nabs approval for CMV fighter Prevymis
Wed, 08 Nov 2017 16:05:06 +0000
Merck & Co. won FDA approval for a new antiviral on Thursday, and while it's not the sort of hepatitis C blockbuster the company may have hoped for a few months ago, it's a potentially lifesaving drug for adults undergoing stem cell transplants.
Senators blast Allergan's tribal deal, social contract as 'hypocrisy'
Wed, 08 Nov 2017 15:59:20 +0000
Five more lawmakers are piling on Allergan for the company's controversial tribal licensing deal. In a letter to CEO Brent Saunders, they're requesting more information on the "unprecedented" deal.
Keryx looks to boost 'disappointing' Auryxia with new iron deficiency launch
Wed, 08 Nov 2017 15:09:54 +0000
Keryx’s Auryxia has so far struggled to get off the ground. But after winning its second FDA approval, the company’s now prepping for a launch that it thinks can take the drug to the next level.
Handing pharma a win, Ohio voters overwhelmingly reject drug pricing measure
Wed, 08 Nov 2017 14:20:59 +0000
Score a win for pharma in the state-by-state war over drug prices. Voters in Ohio, who could have been the latest to slap new state-level rules on drugmakers, instead rejected the ballot measure by a 79% to 21% margin.
Pfizer renews 'Know Pneumonia' campaign with myth-busting creative
Wed, 08 Nov 2017 13:34:29 +0000
Pfizer has relaunched its “Know Pneumonia” disease awareness campaign with a myths-and-facts approach. The new TV commercial shows healthy older people asking myth-type questions including, “Isn’t it like a bad cold or flu?” and “Can I catch it from a pneumococcal vaccination?”
© 2009 Rx Celebs, LLC